Pacylex

Major Grant Awarded to Study PCLX-001 in Acute Myeloid Leukemia Patients

Pacylex today announced that the US Department of Defense (DOD) awarded The University of Texas MD Anderson Cancer Center $1.4 million to treat Acute Myeloid Leukemia (AML) patients with PCLX-001, a first-in-class N-myristoylation inhibitor in clinical development by Pacylex.

Read the full story here.

October 14, 2022